Valérie Maréchal
Pasteur Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Valérie Maréchal.
Journal of Virology | 2001
Valérie Maréchal; Marie-Christine Prévost; Caroline Petit; Emmanuelle Perret; Jean-Michel Heard; Olivier Schwartz
ABSTRACT Whereas human immunodeficiency virus (HIV) infects various cell types by fusion at the plasma membrane, we observed a different entry route in human primary macrophages, in which macropinocytosis is active. Shortly after exposure of macrophages to HIV-1 and irrespective of viral envelope-receptor interactions, particles were visible in intracellular vesicles, which were identified as macropinosomes. Most virions appeared subsequently degraded. However, fusion leading to capsid release in the cytosol and productive infection could take place inside vesicles when particles were properly enveloped. These observations provide new insights into HIV-1 interactions with a cell target relevant to pathogenesis. They may have implications for the design of soluble inhibitors aimed at interfering with the fusion or entry processes.
Journal of Acquired Immune Deficiency Syndromes | 2007
François Rouet; Marie-Laure Chaix; Eric Nerrienet; Nicole Ngo-Giang-Huong; Jean-Christophe Plantier; Marianne Burgard; Martine Peeters; Florence Damond; Didier K. Ekouevi; Philippe Msellati; Laurent Ferradini; Sandra Rukobo; Valérie Maréchal; Nilda Schvachsa; Lahcen Wakrim; Christian Rafalimanana; Benjamin Rakotoambinina; Jean-Paul Viard; Jean-Marie Seigneurin; Christine Rouzioux
The high genetic diversity of HIV-1 has a major impact on the quantification of plasma HIV-1 RNA, representing an increasingly difficult challenge. A total of 898 plasma specimens positive for HIV-1 RNA by commercial assays (Amplicor v1.5; Roche Diagnostic Systems, Alameda, CA or Versant v3.0; Bayer Diagnostics, Emeryville, CA) were tested using the Agence Nationale de Recherches sur le SIDA second-generation (G2) real-time reverse transcriptase polymerase chain reaction (RT-PCR) test: 518 samples containing HIV-1 of known subtype, including 88 from 2 subtype panels and 430 harboring B (n = 266) and non-B (n = 164) group M HIV-1 subtypes from patients followed up in 2002 through 2005 at Necker Hospital (Paris, France), and 380 samples from 10 different countries (Argentina, Cambodia, Cameroon, Central African Republic, France, Ivory Coast, Madagascar, Morocco, Thailand, and Zimbabwe). HIV-1 RNA values obtained by G2 real-time PCR were highly correlated with those obtained by the Amplicor v1.5 for B and non-B subtypes (R2 = 0.892 and 0.892, respectively) and for samples from diverse countries (R2 = 0.867 and 0.893 for real-time PCR vs. Amplicor v1.5 and real-time PCR vs. Versant v3.0, respectively). Approximately 30% of specimens harboring non-B subtypes were underquantified by at least −0.51 log10 in Amplicor v1.5 versus 5% underquantified in G2 real-time PCR. Discrepant results were also obtained with subtype B samples (14% underquantified by Amplicor v1.5 vs. 7% by G2 real-time PCR). Similar percentages were observed when comparing results obtained with the G2 real-time PCR assay with those obtained using the Versant assay. Addressing HIV-1 diversity, continual monitoring of HIV-1 RNA assays, together with molecular epidemiology studies, is required to improve the accuracy of all HIV RNA assays.
Vox Sanguinis | 1988
Yvette Henin; Valérie Maréchal; Françoise Barré-Sinoussi; J.C. Chermann; J.-J. Morgenthaler
Abstract. We studied the inactivation of the etiologic agent of the acquired immunodeficiency syndrome, human immunodeficiency virus, in the course of the Kistler and Nitschmann cold ethanol fractionation of human blood plasma. By measuring reverse transcriptase activity and viral infectivity, we have shown that the virus load is reduced by a factor of 104 during the initial and at least a factor of 106 during the subsequent steps of the fractionation procedure. This loss of virus may be observed in the absence or in the presence of antibodies against human immunodeficiency virus and is due to a combination of chemical inactivation, physical partition, and injury caused by repeated freezing and thawing. The laboratory data therefore further confirm epidemiological studies which indicate that immunoglobulin preparations obtained by ethanol fractionation do not transmit human immunodeficiency virus.
Nature Medicine | 1996
Olivier Schwartz; Valérie Maréchal; Sylvie Le Gall; François A. Lemonnier; Jean-Michel Heard
Journal of Virology | 1995
Olivier Schwartz; Valérie Maréchal; Olivier Danos; Jean Michel Heard
Journal of Virology | 1998
Valérie Maréchal; François Clavel; Jean Michel Heard; Olivier Schwartz
Journal of Virology | 1998
Olivier Schwartz; Valérie Maréchal; Bertrand Friguet; Fernando Arenzana-Seisdedos; Jean-Michel Heard
Journal of Virology | 1995
Olivier Schwartz; Alice Dautry-Varsat; Bruno Goud; Valérie Maréchal; Agathe Subtil; Jean-Michel Heard; Olivier Danos
AIDS Research and Human Retroviruses | 1988
Olivier Schwartz; Yvette Henin; Valérie Maréchal; Luc Montagnier
Virology | 2008
Anne-Claire Brehin; Laetitia Rubrecht; Martha Erika Navarro-Sanchez; Valérie Maréchal; Marie-Pascale Frenkiel; Priscilla Lapalud; Daniel Laune; Amadou A. Sall; Philippe Desprès